Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 2/20 | 0.46 |
| ▸ | IGF1R | P08069 | 6/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 6/20 | 0.40 |
| ▸ | HTR2C | P28335 | 6/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 4/20 | 0.39 |
| ▸ | INSR | P06213 | 1/20 | 0.38 |
| ▸ | BRD2 | P25440 | 1/20 | 0.38 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4907639 | 0.83 | HTR2A (0.42) | ROCK2IGF1RROCK1HTR2AHTR2C | |
| SCHEMBL14214189 | 0.78 | ROCK2 (0.34) | ROCK2ROCK1 | |
| SCHEMBL4909409 | 0.76 | ROCK2 (0.33) | ROCK2ROCK1 | |
| SCHEMBL786855 | 0.75 | HRH4 (0.65) | HTR2AHTR2CHRH4 | |
| SCHEMBL4904846 | 0.74 | BRD4 (0.33) | ROCK2ROCK1BRD4BRD2BRD3 | |
| SCHEMBL786651 | 0.67 | HTR2A (0.59) | HTR2ANPSR1HRH4 | |
| SCHEMBL786532 | 0.67 | IGF1R (0.44) | ROCK2IGF1RHTR2AHTR2CINSR | |
| SCHEMBL12841132 | 0.66 | IGF1R (0.40) | IGF1RINSR | |
| SCHEMBL16540739 | 0.65 | IGF1R (0.83) | IGF1RINSR | |
| SCHEMBL786361 | 0.65 | PAK4 (0.65) | HTR2AHTR2CNPSR1HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080113946-A1 | N-aryl-5,7-dihydrofuro[3,4-d]pyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYNTOVIA, INC. (US) | 2008-05-15 | — | — | US | claimed |
| US-20080113946-A1 | N-aryl-5,7-dihydrofuro[3,4-d]pyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYNTOVIA, INC. (US) | 2008-05-15 | — | — | US | disclosed |
| US-20080113946-A1 | N-aryl-5,7-dihydrofuro[3,4-d]pyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYNTOVIA, INC. (US) | 2008-05-15 | — | — | US | disclosed |
| US-20080113946-A1 | N-aryl-5,7-dihydrofuro[3,4-d]pyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYNTOVIA, INC. (US) | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113946-A1 | N-aryl-5,7-dihydrofuro[3,4-d]pyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP7, API5, CASP5 | ROCK2 3024/4885IGF1R 1146/4885ROCK1 2088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.